Page last updated: 2024-11-04

perhexiline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Perhexiline is a potent antianginal drug that acts as a calcium channel blocker. It is synthesized through a multi-step process involving the reaction of 2,6-dimethylphenol with 2-chloro-1,3-dimethyl-4-(2,2,2-trichloroethoxy)benzene. Perhexiline has been shown to effectively reduce angina symptoms by inhibiting the influx of calcium ions into cardiac muscle cells, thereby reducing myocardial oxygen demand. However, its use is limited due to the risk of hepatotoxicity, which can be severe and potentially life-threatening. Despite this, perhexiline remains an important research subject due to its unique pharmacological profile and potential therapeutic applications in conditions like heart failure and diabetes. Researchers continue to investigate ways to optimize its safety profile and explore alternative routes of administration to reduce the risk of liver damage.'

Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4746
CHEMBL ID75880
CHEBI ID35553
SCHEMBL ID114894
MeSH IDM0016281

Synonyms (71)

Synonym
CHEMBL75880 ,
piperidine, 2-(2,2-dicyclohexylethyl)-
perhexiline
DIVK1C_000542
KBIO1_000542
6621-47-2
CHEBI:35553 ,
2-(2,2-dicyclohexylethyl)piperidine
perhexilene
SPECTRUM_000013
BPBIO1_000212
OPREA1_365504
PRESTWICK3_000286
BSPBIO_000192
IDI1_000542
PRESTWICK2_000286
BSPBIO_003118
SPECTRUM5_001084
AB00053656
DB01074
perhexiline [inn:ban]
perhexilina [inn-spanish]
perhexilinum [inn-latin]
einecs 229-569-5
KBIO2_000353
KBIO3_002618
KBIOSS_000353
KBIO2_005489
KBIOGR_000685
KBIO2_002921
SPECTRUM2_001539
SPECTRUM4_000173
PRESTWICK0_000286
NINDS_000542
SPBIO_001358
SPBIO_002411
SPECTRUM3_001579
PRESTWICK1_000286
perhexiline (inn)
D08340
NCGC00018261-02
39648-47-0
einecs 254-558-7
39648-48-1
(-)-2-(2,2-dicyclohexylethyl)piperidine
(+)-2-(2,2-dicyclohexylethyl)piperidine
einecs 254-559-2
10118-35-1
unii-ku65374x44
ku65374x44 ,
perhexilina
einecs 252-426-3
(1)-2-(2,2-dicyclohexylethyl)piperidine
perhexilline
NCGC00018261-05
perhexiline [mi]
perhexiline [who-dd]
perhexiline [inn]
(+/-)-2-(2,2-dicyclohexylethyl)piperidine
SCHEMBL114894
bdbm61402
cid_5284439
(z)-2-butenedioic acid;2-(2,2-dicyclohexylethyl)piperidine
2-(2,2-dicyclohexylethyl)piperidine;maleic acid
AB00053656_22
DTXSID7023439
SBI-0051794.P002
Q1232737
EN300-18567360
CS-0013087
HY-B1334

Research Excerpts

Overview

Perhexiline is a prophylactic anti-anginal drug known to act by inhibiting carnitine palmitoyltransferase 1 (CPT1) and 2 ( CPT2), mitochondrial enzymes critical for fatty acid metabolism. It is increasingly also used in the treatment of heart failure and hypertrophic cardiomyopathy.

ExcerptReferenceRelevance
"Perhexiline is a prophylactic antianginal agent developed in the 1970s. "( Study of the roles of cytochrome P450 (CYPs) in the metabolism and cytotoxicity of perhexiline.
Chen, S; Guo, L; Li, F; Qin, X; Ren, Z, 2022
)
2.39
"Perhexiline is a prophylactic antianginal drug known to act by inhibiting carnitine palmitoyltransferase 1 (CPT1) and 2 (CPT2), mitochondrial enzymes critical for fatty acid metabolism."( Perhexiline: Old Drug, New Tricks? A Summary of Its Anti-Cancer Effects.
Dhakal, B; Drew, P; Fenix, K; Maddern, G; Price, T; Smith, E; Tomita, Y, 2023
)
3.07
"Perhexiline is a compound with a long clinical track record in angina treatment and commonly described as an FAO inhibitor."( Perhexiline Demonstrates FYN-mediated Antitumor Activity in Glioblastoma.
Buelow, KL; Chinnaiyan, P; Graham, SF; Guastella, AR; Kant, S; Kesarwani, P; Kumar, P; Nakano, I, 2020
)
2.72
"Perhexiline is an anti-anginal drug developed in the late 1960s. "( Mitochondrial dysfunction and apoptosis underlie the hepatotoxicity of perhexiline.
Chen, S; Guo, L; Guo, X; Li, D; Ning, B; Ren, Z; Seo, JE, 2020
)
2.23
"Perhexiline is a coronary vasodilator for angina treatment that was first developed in the 1960s. "( A mechanism of perhexiline's cytotoxicity in hepatic cells involves endoplasmic reticulum stress and p38 signaling pathway.
Chen, S; Guo, L; Pak, S; Ren, Z, 2021
)
2.42
"Perhexiline is a prophylactic anti-anginal drug which is increasingly also used in the treatment of heart failure and hypertrophic cardiomyopathy."( Relationship between plasma, atrial and ventricular perhexiline concentrations in humans: insights into factors affecting myocardial uptake.
Chong, CR; Drury, NE; Frenneaux, MP; Horowitz, JD; Howell, NJ; Licari, G; Pagano, D; Sallustio, BC, 2014
)
1.37
"Perhexiline is a unique anti-anginal agent that is frequently used in the treatment of chronic refractory angina. "( Interaction of terbinafine (anti-fungal agent) with perhexiline: a case report.
Beltrame, JF; Horowitz, JD; Sallustio, B; Sheikh, AR; Westley, I, 2014
)
2.1
"Perhexiline is a prophylactic anti-ischaemic agent with weak calcium antagonist effect which has been increasingly utilised in the management of refractory angina. "( Stereoselective handling of perhexiline: implications regarding accumulation within the human myocardium.
Chong, CR; Drury, NE; Frenneaux, MP; Horowitz, JD; Licari, G; Pagano, D; Sallustio, BC, 2015
)
2.15
"Perhexiline is a drug that is used for treatment of moderate to severe angina pectoris that has not responded to other treatment. "( Determination of perhexiline and its metabolite hydroxyperhexiline in human plasma by liquid chromatography/tandem mass spectrometry.
Barclay, ML; Begg, EJ; Moore, GA; Zhang, M, 2009
)
2.14
"Perhexiline is a potent anti-anginal drug used for treatment of refractory angina and other forms of heart disease. "( Effects of perhexiline-induced fuel switch on the cardiac proteome and metabolome.
Drozdov, I; Dwyer, J; Edwards, LM; Griffiths, J; Langley, SR; Madhu, B; Mayr, M; Mayr, U; Nabeebaccus, A; Shah, AM; Xing, Q; Yin, X, 2013
)
2.22
"Perhexiline is an antianginal agent that displays both saturable and polymorphic metabolism via CYP2D6. "( Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.
Coller, JK; Davies, BJ; Gillis, D; Horowitz, JD; James, HM; Morris, RG; Sallustio, BC; Somogyi, AA, 2004
)
2
"Perhexiline is a prophylactic anti-anginal agent that ameliorates the metabolic basis for myocardial ischaemia and is increasingly used in the management of acute coronary syndromes. "( Development of a regimen for rapid initiation of perhexiline therapy in acute coronary syndromes.
Chandy, S; Horowitz, JD; Morris, R; Philpott, A, 2004
)
2.02
"Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency."( Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.
Ashrafian, H; Campbell, R; Clarke, K; Fraser, AG; Frenneaux, M; Gunaruwan, P; Horowitz, J; Lee, L; Scheuermann-Freestone, M; Taylor, R; Williams, L, 2005
)
1.35
"Perhexiline maleate is an amphiphilic molecule. "( [Study of thesaurismosis induced by perhexiline maleate. Confirmation of experimental data].
Albouz, S; Bajolet, A; Baumann, N; Caulet, T; Pluot, M; Turpin, JC, 1983
)
1.98
"Perhexiline maleate is an antianginal agent which depends on hepatic oxidation for its elimination. "( Impaired oxidation of debrisoquine in patients with perhexiline liver injury.
Morgan, MY; Oates, NS; Reshef, R; Shah, RR; Sherlock, S; Smith, RL, 1984
)
1.96
"Perhexiline maleate is a potent anti-anginal drug which may cause alcoholic-type hepatitis and cirrhosis. "( Perhexiline maleate induced cirrhosis.
Dunn, D; Pieterse, AS; Rowland, R, 1983
)
3.15
"Perhexiline maleate is an agent currently under investigation in Canada that is used for angina unresponsive to other treatment. "( Papilledema without peripheral neuropathy in a patient taking perhexiline maleate.
Colman, J; Mandelcorn, M; Murphy, J, 1982
)
1.95
"Perhexiline maleate is an antianginal drug that has been shown to have antiarrhythmic effects in humans. "( Voltage- and time-dependent block by perhexiline of K+ currents in human atrium and in cells expressing a Kv1.5-type cloned channel.
Dage, RC; Fermini, B; Nattel, S; Rampe, D; Wang, Z; Wible, B, 1995
)
2.01
"Perhexiline maleate (PM) is an anti-anginal agent of amphiphilic character involved in lipidosis disorders. "( Stimulatory effect of perhexiline maleate on the basal and LHRH-stimulated luteinizing hormone release from rat pituitary cell aggregates in vitro.
Girre, A; Rault, B; Saiag, B; Shacoori, V, 1995
)
2.05
"Perhexiline Maleate (Px) is a potent, oxygen-sparing agent used in the management of patients with acute myocardial ischaemia that is resistant to conventional pharmacological therapy. "( Caring for patients with acute myocardial ischaemia: the perhexiline maleate experience.
Stewart, S,
)
1.82
"Perhexiline is a prophylactic antianginal agent particularly useful in patients whose angina is poorly controlled or refractory to conventional drug regimens. "( Assessment of interlaboratory performance in the provision of perhexiline therapeutic drug monitoring services in Australia.
Morris, RG; Sallustio, BC, 1999
)
1.99
"Perhexiline is a potent prophylactic anti-anginal agent that has been shown to inhibit myocardial utilization of long-chain fatty acids and to inhibit the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1. "( Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart.
Horowitz, JD; Kennedy, JA; Kiosoglous, AJ; Murphy, GA; Pelle, MA, 2000
)
2.15
"Perhexiline maleate is an anti-anginal drug believed to cause liver damage. "( The effects of perhexiline maleate (Pexid) and alcohol on rat liver.
McDonald, GS, 1979
)
2.06
"Perhexiline is a lysosomotropic agent which has proved to be very valuable to certain patients suffering from angina pectoris. "( Effects of perhexiline maleate on asialo-orosomucoid receptor endocytosis and recycling in HTC cells.
Blayau, M; Gueble-Val, F; Guenet, L; Le Gall, JY; Le Treut, A; Leray, G; Shacoori, V, 1989
)
2.11

Effects

Perhexiline has been used in France since 1973 and is a second-line drug to be used in cases of intolerance or contraindications to other anti-anginal drugs. It has no significant effect on the mass spectrometry-visible polar myocardial metabolome in vivo in humans.

ExcerptReferenceRelevance
"Perhexiline has no significant effect on the mass spectrometry-visible polar myocardial metabolome in vivo in humans, supporting the suggestion that it acts via a pathway that is independent of myocardial carnitine palmitoyltransferase inhibition and may explain the lack of clinical benefit observed following surgery."( The effect of perhexiline on myocardial protection during coronary artery surgery: a two-centre, randomized, double-blind, placebo-controlled trial.
Calvert, MJ; Drury, NE; Freemantle, N; Frenneaux, MP; Graham, TR; Green, DH; Howell, NJ; Hyde, JA; Lewis, ME; Mascaro, JG; Pagano, D; Rooney, SJ; Senanayake, EL; Viant, MR; Weber, RJ; Wilson, IC, 2015
)
1.5
"Perhexiline has been shown to be an effective anti-anginal agent due to its metabolic modulation properties by inhibiting the uptake of free fatty acids into the mitochondrion, and thereby promoting a more efficient carbohydrate-driven myocardial metabolism."( Multicentre double-blind randomized controlled trial of perhexiline as a metabolic modulator to augment myocardial protection in patients with left ventricular hypertrophy undergoing cardiac surgery.
Bhudia, S; Drury, NE; Freemantle, N; Frenneaux, M; Graham, TR; Green, D; Howell, NJ; Lewis, M; Mascaro, J; Oelofse, T; Pagano, D; Ranasinghe, AM; Rooney, SJ; Senanayake, EL; Wilson, IC, 2015
)
1.38
"Perhexiline has become a "last-line" agent for refractory angina as a result of complex pharmacokinetics and potential toxicity. "( Effects of aging, renal dysfunction, left ventricular systolic impairment, and weight on steady state pharmacokinetics of perhexiline.
Averbuj, P; Chik, W; Horowitz, JD; Ling, LH; Morris, RG; Ngo, DT; Pati, PK; Sallustio, BC; Sverdlov, AL, 2011
)
2.02
"Perhexiline has been used in France since 1973 and is a second-line drug to be used in cases of intolerance or contraindications to other anti-anginal drugs."( [The classic anti-anginal agents and molsidomine].
Vacheron, A, 1983
)
0.99
"Perhexiline has been used as an anti-anginal agent for over 25 years, and is known to cause QT prolongation and torsades de pointes. "( Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate.
Breit, SN; Bursill, JA; Campbell, TJ; Qiu, MR; Singleton, CB; Tie, H; Valenzuela, SM; Walker, BD; Wyse, KR, 1999
)
1.96

Treatment

Perhexiline treatment increased resting and peak dobutamine stress regional myocardial function (by 15% and 24%, respectively) and normalized skeletal muscle phosphocreatine recovery after exercise. Treatment also caused a significant increase in caspase 3/7 activity at 2 h and 4 h.

ExcerptReferenceRelevance
"Perhexiline treatment also caused a significant increase in caspase 3/7 activity at 2 h and 4 h."( Mitochondrial dysfunction and apoptosis underlie the hepatotoxicity of perhexiline.
Chen, S; Guo, L; Guo, X; Li, D; Ning, B; Ren, Z; Seo, JE, 2020
)
1.51
"Perhexiline treatment also increased resting and peak dobutamine stress regional myocardial function (by 15% and 24%, respectively) and normalized skeletal muscle phosphocreatine recovery after exercise."( Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.
Ashrafian, H; Campbell, R; Clarke, K; Fraser, AG; Frenneaux, M; Gunaruwan, P; Horowitz, J; Lee, L; Scheuermann-Freestone, M; Taylor, R; Williams, L, 2005
)
1.35
"Treatment with perhexiline potentiated the cGMP-elevating effects of SNP in platelets (n=9,P =0.03)."( Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide.
Chirkov, YY; Holmes, AS; Horowitz, JD; Kennedy, JA; Stewart, S; Willoughby, SR, 2002
)
0.94
"Treatment with perhexiline led to significant improvements in VO2max (16.1+/-0.6 to 18.8+/-1.1 mL ."( Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.
Ashrafian, H; Campbell, R; Clarke, K; Fraser, AG; Frenneaux, M; Gunaruwan, P; Horowitz, J; Lee, L; Scheuermann-Freestone, M; Taylor, R; Williams, L, 2005
)
0.97

Toxicity

Perhexiline maleate, an antianginal compound, may cause severe adverse effects such as weight loss, hepatic dysfunction and peripheral neuropathy in a small proportion of patients. Mortality rates during long-term therapy are surprisingly low.

ExcerptReferenceRelevance
" With attention to the pharmacokinetics of perhexiline's elimination in individual patients, this novel antianginal agent seems to be safe and effective and deserves further evaluation in patients already receiving maximal antianginal therapy who are not candidates for revascularization procedures."( Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent.
Antman, EM; Beamer, AD; Benfell, K; Cantillon, CO; Cole, PL; Hartley, LH; Kelly, RA; McGowan, N; Smith, TW, 1990
)
0.85
"Perhexiline maleate, an antianginal compound, may cause severe adverse effects such as weight loss, hepatic dysfunction and peripheral neuropathy in a small proportion of patients."( Perhexiline-induced lipidosis in the dark Agouti (DA) rat. An animal model of genetically determined neurotoxicity.
Hess, CW; Meier, C; Preisig, R; Wahllaender, A, 1986
)
3.16
" However, hepatic and neurological adverse effects associated with perhexiline administration led to a marked decline in its use."( Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease.
Killalea, SM; Krum, H, 2001
)
0.8
" The most toxic compounds, the second one, characterized by the smallest variations of TEER, included verapamil and diltiazem."( Influence of different calcic antagonists on the Caco-2 cell monolayer integrity or "TEER, a measurement of toxicity?".
Galmier, MJ; Lartigue, C; Mathieu, F; Pognat, JF,
)
0.13
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"This first audit of a large population treated long-term perhexiline demonstrates the following: (1) Although the frequency of monitoring is less than ideal, therapeutic drug monitoring effectively limits occurrence of toxic drug concentrations and virtually eliminates long-term hepato- and neuro-toxicity and (2) Mortality rates during long-term therapy, notably for patients with concomitant heart failure, are surprisingly low."( Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit.
Choi, BY; Chong, CR; Horowitz, JD; Phuong, H; Raman, B, 2016
)
1.24
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" Treatment of CS complicating PPCM is challenging, as β-adrenergic receptor (β-AR) stimulation seems to be associated with progression of heart failure and adverse outcome."( Perhexiline treatment improves toxic effects of β-adrenergic receptor stimulation in experimental peripartum cardiomyopathy.
Bauersachs, J; Hilfiker-Kleiner, D; List, M; Müller, JH; Pfeffer, TJ; Ricke-Hoch, M; Scherr, M, 2021
)
2.06
" Although, therapeutically, it remained a success, the concerns of its severe adverse effects including hepatotoxicity caused the restricted use of the drug, and eventually its withdrawal from the market in multiple countries."( Study of the roles of cytochrome P450 (CYPs) in the metabolism and cytotoxicity of perhexiline.
Chen, S; Guo, L; Li, F; Qin, X; Ren, Z, 2022
)
0.95

Pharmacokinetics

We have performed single-dose pharmacokinetic studies on perhexiline in eight young volunteers, each given 300 mg of Pexid orally. The three stereoisomeric forms of per hexiline all had the same times to peak plasma concn of the unchanged drug or of the cis-metabolite. All three forms had a similar plasma elimination half-life for unchanged per Hexiline. Cycloalkyl perhexILine analogues 6a-j were found to be unsuitable for further development, as they retained a pharmacokinetics profile very similar to that shown by the parent compound.

ExcerptReferenceRelevance
" The three stereoisomeric forms of perhexiline all had the same times to peak plasma concn of the unchanged drug or of the cis-metabolite, and all three forms had a similar plasma elimination half-life for unchanged perhexiline."( Stereoselective pharmacokinetics of perhexiline.
Amoah, AG; Gould, BJ; Parke, DV, 1986
)
0.82
" These results confirm and extend the existing pharmacokinetic data on perhexiline, especially the bimodal distribution of CL/F manifested via an inherited deficiency in hepatic and extrahepatic CYP2D6 activity."( Population pharmacokinetics of perhexiline from very sparse, routine monitoring data.
Charles, BG; Hussein, R; Morris, RG; Rasiah, RL, 2001
)
0.83
" 2) To determine whether the ratio measured in the first fortnight of treatment (C(i)(OHPx)/C(i)(Px)) may be used to guide patient dosing with perhexiline, a drug with a narrow therapeutic index, long half-life and saturable metabolism via CYP2D6."( Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.
Morris, RG; Sallustio, BC; Westley, IS, 2002
)
0.78
" In this study, dose requirement declined with age in a frail and wasting population as a result of weight-related pharmacokinetic factors."( Effects of aging, renal dysfunction, left ventricular systolic impairment, and weight on steady state pharmacokinetics of perhexiline.
Averbuj, P; Chik, W; Horowitz, JD; Ling, LH; Morris, RG; Ngo, DT; Pati, PK; Sallustio, BC; Sverdlov, AL, 2011
)
0.58
" Cycloalkyl perhexiline analogues 6a-j were found to be unsuitable for further development, as they retained a pharmacokinetic profile very similar to that shown by the parent compound."( Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
Frenneaux, MP; Grant, DM; Greig, IR; Madhani, M; Noordali, H; Sani, M; Tseng, CC; Zanda, M, 2017
)
1.1

Bioavailability

3:1 suggests that hepatic metabolism of perhexiline may be saturable and that the bioavailability of per hexiline is dose dependent.

ExcerptReferenceRelevance
" These products are well absorbed from the gastrointestinal tract but undergo variable degrees of transformation during the first passage through the liver."( [Clinical pharmacology of calcium inhibitors].
Martre, H; Singlas, E; Taburet, AM, 1985
)
0.27
" These findings indicate the occurrence of stereospecific pre-systemic metabolism of perhexiline which reduces the bioavailability of the parent drug."( Further studies on the pharmacokinetics of perhexiline maleate in humans.
Amoah, AG; Gould, BJ; Lockhart, JD; Parke, DV, 1986
)
0.76
"3:1, suggesting that hepatic metabolism of perhexiline may be saturable and that the bioavailability of perhexiline is dose dependent."( High-performance liquid chromatographic assay of perhexiline maleate in plasma.
Drummer, OH; Goble, AJ; Horowitz, JD; Louis, WJ; Morris, PM, 1981
)
0.78
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

In a preliminary study which lasted 14 weeks, an anti-anginal preparation, perhexiline maleate (Pexid), was prescribed in a dosage of 200 mg twice a day to 7 patients who were suffering from cardiac arrhythmias associated with ischaemic heart disease. Compared with patients with at least two functional CYP2D6 genes, those with one functional gene were on similar per hexiline dosage regimens but had significantly higher plasma per Hexiline concentrations.

ExcerptRelevanceReference
"In a preliminary study which lasted 14 weeks, an anti-anginal preparation, perhexiline maleate (Pexid), was prescribed in a dosage of 200 mg twice a day to 7 patients who were suffering from cardiac arrhythmias associated with ischaemic heart disease."( The anti-arrhythmic effects of perhexiline maleate in patients with ischaemic heart disease.
Gitlin, N, 1975
)
0.77
" A second group of patients (n = 19) were treated chronically with 50-400 mg/day of perhexiline, dosage being adjusted to minimize symptoms."( Perhexiline maleate treatment for severe angina pectoris--correlations with pharmacokinetics.
Goble, AJ; Horowitz, JD; Louis, WJ; Macdonald, PS; Sia, ST, 1986
)
1.94
" The likelihood of side effects may be decreased by using this dosage regimen."( Therapy of angina pectoris with low-dose perhexiline.
Horgan, JH; O'Callaghan, WG; Teo, KK,
)
0.4
" Dosing guidelines for all drugs are given in the paper."( Diagnosis and treatment of Prinzmetal's variant angina.
Greenberg, B; McMahon, MT; McPherson, MA; Sheaffer, SL; Talbert, RL,
)
0.13
"Elderly patients with symptomatic severe aortic stenosis, who were deemed unsuitable for aortic valve replacement, were treated with perhexiline, the drug dosage titrated according to steady state plasma perhexiline concentrations."( Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis.
Horowitz, JD; Robinson, MA; Unger, SA, 1997
)
1.94
" 2) To determine whether the ratio measured in the first fortnight of treatment (C(i)(OHPx)/C(i)(Px)) may be used to guide patient dosing with perhexiline, a drug with a narrow therapeutic index, long half-life and saturable metabolism via CYP2D6."( Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.
Morris, RG; Sallustio, BC; Westley, IS, 2002
)
0.78
" It also supports the calculation of the hydroxyperhexiline : perhexiline ratio (in patients at steady state) on blood samples taken at any time during the dosing interval."( Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady state.
Horowitz, JD; Jones, TE; Morris, RG, 2004
)
0.87
" While C0 is probably the best time for therapeutic drug monitoring purposes, it is not unreasonable to use samples drawn at any time during the dosing interval."( Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady state.
Horowitz, JD; Jones, TE; Morris, RG, 2004
)
0.61
" Two patients presenting to hospital with single-dose over-dosage of perhexiline (6500 mg and 1000 mg, respectively) provided a basis for examining the safety of large single dosage of perhexiline and associated time-course of drug levels."( Development of a regimen for rapid initiation of perhexiline therapy in acute coronary syndromes.
Chandy, S; Horowitz, JD; Morris, R; Philpott, A, 2004
)
0.81
" Perhexiline may therefore represent a novel treatment for CHF with a good safety profile, provided that the dosage is adjusted according to plasma levels."( Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.
Ashrafian, H; Campbell, R; Clarke, K; Fraser, AG; Frenneaux, M; Gunaruwan, P; Horowitz, J; Lee, L; Scheuermann-Freestone, M; Taylor, R; Williams, L, 2005
)
1.54
" Ideal therapeutics involves tailoring the drug and its dosing to the individual patient, taking into account this variability."( Individualized drug and dose: the clinical pharmacologist's calling or curse?
Begg, EJ, 2005
)
0.33
" The application of this method to plasma and urine samples of five CYP2D6 extensive metaboliser (EM) patients at steady state with respect to PHX dosing determined that the mean (+/-S."( Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography.
Coller, JK; Davies, BJ; Herbert, MK; Milne, RW; Sallustio, BC; Somogyi, AA, 2006
)
0.59
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
"In a prospective study, steady-state plasma concentrations of (+) and (-)-perhexiline were quantified in 10 CYP2D6 genotyped patients following dosing with 100 mg/day rac-perhexiline maleate, and following a subsequent dosage increase to 150 or 200 mg/day."( Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
Coller, JK; Davies, BJ; Herbert, MK; Horowitz, JD; Inglis, SC; James, HM; Milne, RW; Morris, RG; Sallustio, BC; Somogyi, AA, 2007
)
0.79
" Following the dosage increase, the median CL/F of both enantiomers decreased by 45."( Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
Coller, JK; Davies, BJ; Herbert, MK; Horowitz, JD; Inglis, SC; James, HM; Milne, RW; Morris, RG; Sallustio, BC; Somogyi, AA, 2007
)
0.56
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
cardiovascular drugA drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
piperidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (30)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fumarate hydrataseHomo sapiens (human)Potency11.77040.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency29.41070.00529.466132.9993AID1347411
EWS/FLI fusion proteinHomo sapiens (human)Potency16.63110.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
polyproteinZika virusPotency11.77040.00308.794948.0869AID1347053
Interferon betaHomo sapiens (human)Potency29.41070.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)14.36000.11007.190310.0000AID1449628
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)1.48520.00000.536910.0000AID625184
Tyrosine-protein kinase FynHomo sapiens (human)IC50 (µMol)4.06400.00021.67898.6800AID625185
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)3.29420.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki3.26700.00322.28879.3160AID625207
Muscarinic acetylcholine receptor M4Homo sapiens (human)IC50 (µMol)3.59190.00001.15467.5858AID625154
Muscarinic acetylcholine receptor M4Homo sapiens (human)Ki0.50090.00000.79519.1201AID625154
Muscarinic acetylcholine receptor M5Homo sapiens (human)IC50 (µMol)1.09320.00010.99178.0000AID625155
Muscarinic acetylcholine receptor M5Homo sapiens (human)Ki0.78540.00000.72926.9183AID625155
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)6.38000.00022.45859.9600AID1804171
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)0.94080.00002.015110.0000AID625249
Muscarinic acetylcholine receptor M1Homo sapiens (human)IC50 (µMol)2.71050.00001.403910.0000AID625151
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki0.65280.00000.59729.1201AID625151
Ribosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)IC50 (µMol)148.00000.00271.62879.9000AID719701
Carnitine O-palmitoyltransferase 2, mitochondrialRattus norvegicus (Norway rat)IC50 (µMol)79.00000.38002.09335.1000AID719700
DRattus norvegicus (Norway rat)IC50 (µMol)7.76250.00030.50267.7625AID243189
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)7.76250.00031.09147.7625AID243189
Muscarinic acetylcholine receptor M3Homo sapiens (human)IC50 (µMol)3.11860.00011.01049.9280AID625153
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki0.66100.00000.54057.7600AID625153
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)7.76250.00031.09147.7625AID243189
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)7.76250.00031.06917.7625AID243189
Carnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)IC50 (µMol)72.80000.16002.03003.9000AID719674
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)3.29420.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki3.26700.00031.465610.0000AID625207
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)IC50 (µMol)7.76250.00070.97749.7000AID243189
Carnitine O-palmitoyltransferase 1, liver isoform Rattus norvegicus (Norway rat)IC50 (µMol)112.50000.04000.06500.0900AID719701; AID719702
Carnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)IC50 (µMol)89.50001.05001.05001.0500AID719700; AID719720
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)7.76870.00091.901410.0000AID161281; AID222148; AID243189; AID408340; AID420668; AID576612
Carnitine O-palmitoyltransferase 1, muscle isoformRattus norvegicus (Norway rat)IC50 (µMol)11.00000.38002.03255.1000AID1460781
Carnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)IC50 (µMol)100.00000.12594.244010.0000AID719719
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)2.59920.00030.70285.3660AID625223
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki1.09240.00000.490110.0000AID625223
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (290)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
response to singlet oxygenTyrosine-protein kinase FynHomo sapiens (human)
neuron migrationTyrosine-protein kinase FynHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase FynHomo sapiens (human)
heart processTyrosine-protein kinase FynHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
calcium ion transportTyrosine-protein kinase FynHomo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
axon guidanceTyrosine-protein kinase FynHomo sapiens (human)
learningTyrosine-protein kinase FynHomo sapiens (human)
feeding behaviorTyrosine-protein kinase FynHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase FynHomo sapiens (human)
gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of hydrogen peroxide biosynthetic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase FynHomo sapiens (human)
protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
forebrain developmentTyrosine-protein kinase FynHomo sapiens (human)
T cell costimulationTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase FynHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusTyrosine-protein kinase FynHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein kinase FynHomo sapiens (human)
response to ethanolTyrosine-protein kinase FynHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
dendrite morphogenesisTyrosine-protein kinase FynHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
activated T cell proliferationTyrosine-protein kinase FynHomo sapiens (human)
modulation of chemical synaptic transmissionTyrosine-protein kinase FynHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase FynHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTyrosine-protein kinase FynHomo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase FynHomo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein targeting to membraneTyrosine-protein kinase FynHomo sapiens (human)
dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to nucleusTyrosine-protein kinase FynHomo sapiens (human)
regulation of glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to L-glutamateTyrosine-protein kinase FynHomo sapiens (human)
cellular response to glycineTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to membraneTyrosine-protein kinase FynHomo sapiens (human)
regulation of calcium ion import across plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activityTyrosine-protein kinase FynHomo sapiens (human)
innate immune responseTyrosine-protein kinase FynHomo sapiens (human)
cell differentiationTyrosine-protein kinase FynHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M4Homo sapiens (human)
cell surface receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M4Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M4Homo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
quinone catabolic processRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
long-chain fatty acid metabolic processCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
in utero embryonic developmentCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
fatty acid beta-oxidationCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
carnitine shuttleCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
carnitine metabolic processCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
positive regulation of cold-induced thermogenesisCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
response to hypoxiaCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
long-chain fatty acid metabolic processCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
glucose metabolic processCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
fatty acid beta-oxidationCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
triglyceride metabolic processCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
carnitine shuttleCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
response to nutrientCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
response to xenobiotic stimulusCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
carnitine metabolic processCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
regulation of lipid storageCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
response to organic cyclic compoundCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
epithelial cell differentiationCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
positive regulation of fatty acid beta-oxidationCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
eating behaviorCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
response to alkaloidCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
positive regulation of innate immune responseCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
response to ethanolCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
aflatoxin metabolic processCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
regulation of insulin secretionCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
cellular response to fatty acidCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
liver regenerationCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
response to tetrachloromethaneCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
fatty acid metabolic processCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
fatty acid metabolic processCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
fatty acid beta-oxidationCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
carnitine shuttleCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
carnitine metabolic processCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
response to blue lightCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
long-chain fatty acid transportCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (101)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
protein bindingTyrosine-protein kinase FynHomo sapiens (human)
ATP bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase FynHomo sapiens (human)
enzyme bindingTyrosine-protein kinase FynHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
identical protein bindingTyrosine-protein kinase FynHomo sapiens (human)
alpha-tubulin bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase FynHomo sapiens (human)
transmembrane transporter bindingTyrosine-protein kinase FynHomo sapiens (human)
metal ion bindingTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
tau protein bindingTyrosine-protein kinase FynHomo sapiens (human)
tau-protein kinase activityTyrosine-protein kinase FynHomo sapiens (human)
growth factor receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
scaffold protein bindingTyrosine-protein kinase FynHomo sapiens (human)
disordered domain specific bindingTyrosine-protein kinase FynHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
dihydronicotinamide riboside quinone reductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
zinc ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
electron transfer activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activity, acting on other nitrogenous compounds as donorsRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
chloride ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein homodimerization activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
FAD bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
melatonin bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
resveratrol bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
NAD(P)H dehydrogenase (quinone) activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
carnitine O-palmitoyltransferase activityCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
protein bindingCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
carnitine O-octanoyltransferase activityCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
acyltransferase activityCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
carnitine O-palmitoyltransferase activityCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
protein-macromolecule adaptor activityCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
identical protein bindingCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
palmitoleoyltransferase activityCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
carnitine O-palmitoyltransferase activityCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
protein bindingCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (67)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
nucleusTyrosine-protein kinase FynHomo sapiens (human)
mitochondrionTyrosine-protein kinase FynHomo sapiens (human)
endosomeTyrosine-protein kinase FynHomo sapiens (human)
cytosolTyrosine-protein kinase FynHomo sapiens (human)
actin filamentTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
postsynaptic densityTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
perikaryonTyrosine-protein kinase FynHomo sapiens (human)
cell bodyTyrosine-protein kinase FynHomo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase FynHomo sapiens (human)
perinuclear endoplasmic reticulumTyrosine-protein kinase FynHomo sapiens (human)
glial cell projectionTyrosine-protein kinase FynHomo sapiens (human)
Schaffer collateral - CA1 synapseTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
nucleoplasmRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
extracellular exosomeRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
nucleoplasmCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
nucleolusCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
mitochondrionCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
mitochondrionCarnitine O-palmitoyltransferase 2, mitochondrialHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
mitochondrionCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
mitochondrial outer membraneCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
membraneCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
mitochondrionCarnitine O-palmitoyltransferase 1, liver isoformHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
mitochondrionCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
mitochondrial outer membraneCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
mitochondrionCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (126)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1460777Drug uptake in BALB/c mouse myocardium at 10 mg/kg, po administered via gavage every 24 hrs for 7 days measured 1 hr post last dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1460781Inhibition of Wistar rat heart mitochondrial CPT-1 assessed as reduction in conversion of palmitoyl CoA and L-carnitine into palmitoylcarnitine preincubated for 3 mins followed by L-carnitine and palmitoyl CoA addition measured for 3.5 mins by spectrophot2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID540238Phospholipidosis-positive literature compound observed in mouse
AID60462In vivo percent coronary flow in Mongrel dogs after administration at 3 mg/Kg (iv)1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Synthesis and cardiovascular activity of a new series of cyclohexylaralkylamine derivatives related to perhexiline.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1460801Cardioprotective activity in Langendorff perfused C57BL/6 mouse heart assessed as increase in cardiac contractility at 2 uM perfused for 30 mins in presence of high fat relative to control2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID222148K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.12002Journal of medicinal chemistry, Aug-29, Volume: 45, Issue:18
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
AID1460791Plasma concentration in Sprague-Dawley rat at 10 mg/kg, po administered via gavage every 24 hrs measured at 4 hrs post last dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1460787AUC (0 to 24 hrs) in BALB/c mouse plasma at 10 mg/kg, po administered via gavage every 24 hrs for 7 days measured post last dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1460796Ratio of drug level in myocardium to plasma in BALB/c mouse at 10 mg/kg, po administered via gavage every 24 hrs for 7 days measured 4 hrs post last dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID243189Inhibition of partially open human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel)2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
A two-state homology model of the hERG K+ channel: application to ligand binding.
AID719672Cytotoxicity in human KB cells2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1636452Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 12.2 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1460795Ratio of drug level in myocardium to plasma in BALB/c mouse at 10 mg/kg, po administered via gavage every 24 hrs for 7 days measured 1 hr post last dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1460794Drug uptake in Sprague-Dawley rat myocardium at 10 mg/kg, po administered via gavage every 24 hrs measured at 8 hrs post last dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1460792Plasma concentration in Sprague-Dawley rat at 10 mg/kg, po administered via gavage every 24 hrs measured at 8 hrs post last dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID33263Alpha adrenergic receptor activity in rat aorta1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Synthesis and pharmacological properties of "soft drug" derivatives related to perhexiline.
AID420669Lipophilicity, log D at pH 7.02009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID1460782Plasma concentration in BALB/c mouse at 10 mg/kg, po administered via gavage every 24 hrs for 7 days measured at 1 hr post last dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1460788AUC (0 to 24 hrs) in BALB/c mouse myocardium at 10 mg/kg, po administered via gavage every 24 hrs for 7 days measured post last dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1460790Plasma concentration in Sprague-Dawley rat at 10 mg/kg, po administered via gavage every 24 hrs measured at 2 hrs post last dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID719671Inhibition of rat FAO2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1460797Ratio of drug level in myocardium to plasma in BALB/c mouse at 10 mg/kg, po administered via gavage every 24 hrs for 7 days measured 8 hrs post last dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID719674Inhibition of human CPT22011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1460785Drug uptake in BALB/c mouse myocardium at 10 mg/kg, po administered via gavage every 24 hrs for 7 days measured 4 hrs post last dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1460786Drug uptake in BALB/c mouse myocardium at 10 mg/kg, po administered via gavage every 24 hrs for 7 days measured 8 hrs post last dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1460784Plasma concentration in BALB/c mouse at 10 mg/kg, po administered via gavage every 24 hrs for 7 days measured 8 hrs post last dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID161281Inhibition of human Potassium channel HERG expressed in mammalian cells2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID420668Inhibition of human ERG in MCF7 cells2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID1460780Drug metabolism assessed as human CYP2D6-mediated compound degradation by measuring half life at 5 uM up to 45 mins in presence of NADPH by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1460798Ratio of drug level in myocardium to plasma in in Sprague-Dawley rat at 10 mg/kg, po administered via gavage every 24 hrs measured at 1 hr post dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1460799Ratio of drug level in myocardium to plasma in in Sprague-Dawley rat at 10 mg/kg, po administered via gavage every 24 hrs measured at 8 hrs post dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1460802Cardioprotective activity in Langendorff perfused C57BL/6 mouse heart assessed as increase in cardiac relaxation at 2 uM perfused for 30 mins in presence of high fat relative to control2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID719719Inhibition of human CPT1B2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719702Inhibition of CPT1 in rat cardiac mitochondria using [3H]carnitine by radiometric method2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID719700Inhibition of CPT2 in rat mitochondria using [3H]carnitine by radiometric method2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719673Inhibition of human FAO2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID1460793Drug uptake in Sprague-Dawley rat myocardium at 10 mg/kg, po administered via gavage every 24 hrs measured at 1 hr post last dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1636504Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 9.7 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1460800Ratio of AUC (0 to 24 hrs) in myocardium to plasma in BALB/c mouse at 10 mg/kg, po administered via gavage every 24 hrs for 7 days measured post last dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1460779Half life in Sprague-Dawley rat liver microsomes at 3 uM up to 45 mins in presence of NADPH by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID408340Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Support vector machines classification of hERG liabilities based on atom types.
AID540236Phospholipidosis-positive literature compound observed in human
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1460789Plasma concentration in Sprague-Dawley rat at 10 mg/kg, po administered via gavage every 24 hrs measured at 1 hr post dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID540237Phospholipidosis-positive literature compound observed in rat
AID1460778Half life in human liver microsomes at 3 uM up to 45 mins in presence of NADPH by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID159414Antagonism of calcium-induced contraction of a depolarized coronary in pig1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Synthesis and cardiovascular activity of a new series of cyclohexylaralkylamine derivatives related to perhexiline.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID172459Alpha-adrenolytic activity (pA2) on the descending thoracic branch of the rat aorta1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Synthesis and cardiovascular activity of a new series of cyclohexylaralkylamine derivatives related to perhexiline.
AID643383Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
AID1636394Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 7.6 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1460783Plasma concentration in BALB/c mouse at 10 mg/kg, po administered via gavage every 24 hrs for 7 days measured 4 hrs post last dose by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1460805Cardioprotective activity against Langendorff perfused C57BL/6 mouse heart assessed as lusitropic effect at 2 uM measured for 40 mins reperfusion period in presence of high fat2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID719701Inhibition of CPT1 in rat liver mitochondria using [3H]carnitine by radiometric method2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719720Inhibition of human CPT1A2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID493017Wombat Data for BeliefDocking2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1804171DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: \\Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.\\2020Antimicrobial agents and chemotherapy, 06-23, Volume: 64, Issue:7
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (519)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990338 (65.13)18.7374
1990's31 (5.97)18.2507
2000's58 (11.18)29.6817
2010's67 (12.91)24.3611
2020's25 (4.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.64 (24.57)
Research Supply Index6.50 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index74.75 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials92 (16.08%)5.53%
Reviews57 (9.97%)6.00%
Case Studies86 (15.03%)4.05%
Observational0 (0.00%)0.25%
Other337 (58.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure With Preserved Left Ventricular Function [NCT02862600]Phase 235 participants (Actual)Interventional2016-08-01Terminated(stopped due to Lack of Efficacy)
A Study on the Efficacy, Safety, and Tolerability of Perhexiline Maleate in Subjects With Hypertrophic Cardiomyopathy and Moderate-To-Severe Heart Failure [NCT02431221]Phase 30 participants (Actual)InterventionalWithdrawn(stopped due to Lack of efficacy in a preceding study.)
Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy [NCT00989508]Phase 2/Phase 3220 participants (Anticipated)Interventional2009-10-31Recruiting
Metabolic Manipulation in Chronic Heart Failure [NCT00841139]Phase 250 participants (Actual)Interventional2009-02-28Completed
Mechanisms Responsible for Cardiac and Skeletal Muscle Energetic Impairment in Diabetes [NCT00628056]Phase 1/Phase 275 participants (Anticipated)Interventional2006-10-31Recruiting
Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery [NCT00845364]Phase 2/Phase 3290 participants (Actual)Interventional2007-02-28Completed
Randomised Double Blind Placebo Controlled Trial of Perhexiline in Heart Failure With Preserved Ejection Fraction Syndrome (HFpEF) [NCT00839228]Phase 270 participants (Anticipated)Interventional2009-03-31Completed
Metabolic Alteration With Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy (METAL-HCM Study) [NCT00500552]Phase 244 participants (Anticipated)Interventional2006-12-31Completed
Randomised Controlled Trial of pErhexiline on regreSsion Of Left Ventricular hypErtrophy (LVH) in Patients With Symptomatic Hypertrophic CardioMyopathy (RESOLVE-HCM) [NCT04426578]Phase 260 participants (Anticipated)Interventional2020-12-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02862600 (4) [back to overview]Change From Baseline in the Six-minute Walk Test at the End of Period 1
NCT02862600 (4) [back to overview]Change From Baseline in the Six-minute Walk Test at the End of Period 2
NCT02862600 (4) [back to overview]Change From Baseline of VO2MAX at 16 Weeks
NCT02862600 (4) [back to overview]Change From Baseline of VO2MAX at End of Period 1

Change From Baseline in the Six-minute Walk Test at the End of Period 1

At the conclusion of 8 weeks of perhexiline treatment, 6MWD was measured and compared to 6MWD measured at baseline. (NCT02862600)
Timeframe: end of Period 1 (Week 8)

Interventionmeters (Mean)
Perhexiline--8 Weeks16

[back to top]

Change From Baseline in the Six-minute Walk Test at the End of Period 2

At the conclusion of 16 weeks of perhexiline treatment, 6MWD was measured and compared to 6MWD measured at baseline. (NCT02862600)
Timeframe: end of Period 2 (Week 16)

Interventionmeters (Mean)
Perhexiline--16 Weeks27

[back to top]

Change From Baseline of VO2MAX at 16 Weeks

At the conclusion of 16 weeks of perhexiline treatment, MVO2 was measured using CPEX and compared to MVO2 measured at baseline. (NCT02862600)
Timeframe: end of Period 2 (Week 16)

Interventionml/kg/min (Mean)
Perhexiline--16 Weeks-0.2

[back to top]

Change From Baseline of VO2MAX at End of Period 1

At the conclusion of 8 weeks of perhexiline treatment, MVO2 was measured using CPEX and compared to MVO2 measured at baseline. (NCT02862600)
Timeframe: end of Period 1 (Week 8)

Interventionml/kg/min (Mean)
Perhexiline--8 Weeks0.3

[back to top]